Table 2

DAS28(CRP) and ACR response rates at weeks 20 and 32

Certolizumab pegol–IR plus bimekizumab
(n=52)
Certolizumab pegol–IR plus placebo
(n=27)
DAS28(CRP) <3.2, n (%)
 Week 2021 (45.7)7 (29.2)
 Week 3226 (60.5)11 (47.8)
ACR20, n (%)
 Week 2026 (60.5)13 (54.2)
 Week 3225 (62.5)15 (65.2)
ACR50, n (%)
 Week 2015 (34.9)2 (8.3)
 Week 3216 (40.0)6 (26.1)
ACR70, n (%)
 Week 206 (14.0)0
 Week 3211 (27.5)5 (21.7)
  • ACR20, ACR50, ACR70, American College of Rheumatology 20%, 50% and 70% improvement criteria.

  • DAS28(CRP), Disease Activity Score 28-joint count (C-reactive protein).